On August 14, 2022, the company received a generous investment of $700,000 from one investor through a private placement. He purchased shares at $1.00 and received 20% bonus shares, 700,000 shares and 140,000 shares, respectively, totaling 840,000 shares.
The incoming funds will be used to advance the company’s Phase 2 Human Clinical Studies, study drug manufacturing, and expand the company’s pipeline with the filing of a new patent application, the indication to be announced soon. “I would like to thank our investor for their generous investment. The company will benefit with more working capital tracking us along a faster path to our next milestone”, said Ben Chang, CEO.
